Chinese maker of medical dressings, cotton products and disposable protective and hygiene consumables.
Chinese maker of medical dressings, cotton products and disposable protective and hygiene consumables.
In one line: A Chinese Cardinal Health-lite for wound-care/disposable consumables.
Moat: none. Commodity medical-consumables manufacturing with limited pricing power.
Headquarters: Shaoxing, Zhejiang, China · Employees: 7,909
Size Zhende Medical (603301.SS) is a China Health Care company (Medical Specialties) with a market value of $3.26B, the 743rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥82.90 on 18 Nov 2026.
Performance Over six months the shares fell 9.8%, against +11.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 7.7% over the last twelve months (peer median +7.2%); the operating margin is 7.3% (peer median 7.4%).
Valuation It trades at 42.5× forward earnings against a peer median of 25.7× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +39 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points below its cost of capital (7.1% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.65B | CN¥4.31B | CN¥4.25B | CN¥4.11B | CN¥6.11B |
| Revenue growth | — | +1% | +3% | -33% | — |
| Gross profit | CN¥1.74B | CN¥1.32B | CN¥1.33B | CN¥1.32B | CN¥2.03B |
| EBITDA | n/a | CN¥604M | CN¥603M | CN¥460M | CN¥1.01B |
| Net income | CN¥295M | CN¥261M | CN¥385M | CN¥198M | CN¥680M |
| Free cash flow | CN¥139M | -CN¥5.42M | -CN¥309M | -CN¥147M | CN¥492M |
| Capital expenditure | CN¥347M | CN¥550M | CN¥770M | CN¥599M | CN¥754M |
| Total debt | CN¥1.43B | CN¥1.34B | CN¥625M | CN¥666M | CN¥647M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhende Medical 603301.SS | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% |
| Winner Medical 300888.SZ | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% |
| Intco Medical Technology 300677.SZ | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% |
| Shandong Weigao Group Medical Polymer 1066.HK | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% |
| ConvaTec CTEC.L | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603301.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.6% | -3.4% | 8th highest of 21 |
| 6-month return | -9.8% | +11.1% | 7th lowest of 21 |
| Distance from 52-week high | -20.9% | -27.7% | 8th highest of 21 |
| Revenue growth (TTM) | +7.7% | +7.2% | 10th highest of 20 |
| Operating margin | 7.3% | 7.4% | 10th highest of 19 |
| Forward P/E | 42.5× | 25.7× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 22.9% | 12.5% | 7th most demanding of 16 |
| Growth delivered (Del g) | -16.1% | +8.9% | lowest of 16 |
| Hurdle (Req g minus delivered) | +39.0 pp | +1.6 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | -0.5 pp | -2.1 pp | 5th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |